Skip to main content
SpringerLink
Log in

Surgical Management of Head and Neck Melanoma

  • Chapter
  • First Online:
Melanoma

  • 1646 Accesses

Abstract

Cutaneous malignancies are the most common group of cancers diagnosed in the head and neck. While basal and squamous cell carcinomas represent the most frequent diagnoses, cutaneous melanoma is responsible for the majority of disease-related mortality. Much of the data informing the workup and management of head and neck melanoma is extrapolated from large trials which include mostly trunk and extremity subsites. The anatomical constraints and intricacies of the head and neck region, however, require careful interpretation of the evidence to apply these treatment paradigms to care of the head and neck melanoma patient. Achieving appropriate resection margins and planning reconstructive efforts may present unique challenges. Sentinel node biopsy has proven to be safe and effective for regional nodal staging in the head and neck. Nonetheless, management of the cervical and parotid lymphatic basins requires a detailed understanding of the critical neurovascular structures involved and the potential drainage pathways. Similar to other sites, adjuvant therapy plays an important and expanding role in the management of head and neck melanoma. Clinical trials in systemic therapy, including immunomodulators and targeted inhibitors, provide future directions in the prevention and treatment of recurrent and metastatic disease. Currently, the management of head and neck melanoma requires a coordinated multidisciplinary approach and a comprehensive understanding of the available data to interpret and appropriately apply the evidence to individual patient care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wu X, Elkin EE, Marghoob AA. Burden of basal cell carcinoma in USA. Future Oncol. 2015;11(22):2967–74.

    Article  PubMed  CAS  Google Scholar 

  2. Mydlarz WK, Weber RS, Kupferman ME. Cutaneous malignancy of the head and neck. Surg Oncol Clin N Am. 2015;24(3):593–613.

    Article  PubMed  Google Scholar 

  3. Ekwueme DU, Guy GP, Li C, Rim SH, Parelkar P, Chen SC. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol. 2011;65(5 Suppl 1):S133–43.

    PubMed  Google Scholar 

  4. Zenga J, Nussenbaum B, Cornelius LA, Linette GP, Desai SC. Management controversies in head and neck melanoma: a systematic review. JAMA Facial Plast Surg. 2017;19(1):53–62.

    Article  PubMed  Google Scholar 

  5. Gillgren P, Drzewiecki KT, Niin M, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet. 2011;378(9803):1635–42.

    Article  PubMed  Google Scholar 

  6. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med. 1988;318(18):1159–62.

    Article  PubMed  CAS  Google Scholar 

  7. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8–2.0 mm. Cancer. 2000;89(7):1495–501.

    Article  PubMed  CAS  Google Scholar 

  8. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2003;97(8):1941–6.

    Article  PubMed  Google Scholar 

  9. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001;8(2):101–8.

    CAS  PubMed  Google Scholar 

  10. Thomas JM, Newton-Bishop J, A’Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350(8):757–66.

    Article  PubMed  CAS  Google Scholar 

  11. Hayes AJ, Maynard L, Coombes G, et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol. 2016;17(2):184–92.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Group AaNZMT. MelmarT melanoma margins trial investigating 1 cm v 2 cm wide excision margins for primary cutaneous melanoma. https://clinicaltrials.gov/ct2/show/NCT02385214?term=melmarT&rank=1. Accessed 14 Nov 2015.

  13. Sladden MJ, Balch C, Barzilai DA, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev. 2009;4:CD004835.

    Google Scholar 

  14. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg. 2003;46(6):419–26.

    PubMed  PubMed Central  Google Scholar 

  15. Mocellin S, Pasquali S, Nitti D. The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins. Ann Surg. 2011;253(2):238–43.

    Article  PubMed  Google Scholar 

  16. Lens MB, Dawes M, Goodacre T, Bishop JA. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. Arch Surg. 2002;137(10):1101–5.

    Article  PubMed  Google Scholar 

  17. Melanoma NPM. NCCN clinical practice guidelines in oncology: melanoma. 2017; http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf

  18. Ross MI, Balch CM. Excision margins of melanoma make a difference: new data support an old paradigm. Ann Surg Oncol. 2016;23(4):1053–6.

    Article  PubMed  Google Scholar 

  19. Rawlani R, Rawlani V, Qureshi HA, Kim JY, Wayne JD. Reducing margins of wide local excision in head and neck melanoma for function and cosmesis: 5-year local recurrence-free survival. J Surg Oncol. 2015;111(7):795–9.

    Article  PubMed  Google Scholar 

  20. Teng J, Halbert T, McMurry TL, Levine PA, Christophel JJ. Histopathologic margin distance in survival in resection of cutaneous melanoma of the head and neck. Laryngoscope. 2015;125(8):1856–60.

    Article  PubMed  Google Scholar 

  21. Prieto VG, Argenyi ZB, Barnhill RL, et al. Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? Am J Clin Pathol. 2003;120(2):203–8.

    Article  PubMed  Google Scholar 

  22. Chin-Lenn L, Murynka T, McKinnon JG, Arlette JP. Comparison of outcomes for malignant melanoma of the face treated using Mohs micrographic surgery and wide local excision. Dermatol Surg. 2013;39(11):1637–45.

    Article  PubMed  CAS  Google Scholar 

  23. Etzkorn JR, Sobanko JF, Elenitsas R, et al. Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment. J Am Acad Dermatol. 2015;72(5):840–50.

    Article  PubMed  CAS  Google Scholar 

  24. Möller MG, Pappas-Politis E, Zager JS, et al. Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol. 2009;16(6):1526–36.

    Article  PubMed  Google Scholar 

  25. Parrett BM, Kashani-Sabet M, Leong SP, Buncke N, Singer MI. The safety of and indications for immediate reconstruction of head and neck melanoma defects: our early experience. Ann Plast Surg. 2014;72(Suppl 1):S35–7.

    Article  PubMed  CAS  Google Scholar 

  26. Sullivan SR, Scott JR, Cole JK, et al. Head and neck malignant melanoma: margin status and immediate reconstruction. Ann Plast Surg. 2009;62(2):144–8.

    Article  PubMed  CAS  Google Scholar 

  27. Christophel JJ, Johnson AK, McMurry TL, Park SS, Levine PA. Predicting positive margins in resection of cutaneous melanoma of the head and neck. Laryngoscope. 2013;123(3):683–8.

    Article  PubMed  Google Scholar 

  28. Brown CD, Zitelli JA. The prognosis and treatment of true local cutaneous recurrent malignant melanoma. Dermatol Surg. 1995;21(4):285–90.

    Article  PubMed  CAS  Google Scholar 

  29. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982;49(11):2420–30.

    Article  PubMed  CAS  Google Scholar 

  30. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61(9):697–705.

    Article  PubMed  CAS  Google Scholar 

  31. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. 1998;351(9105):793–6.

    Article  PubMed  CAS  Google Scholar 

  32. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7(2):87–97.

    Article  PubMed  CAS  Google Scholar 

  33. Klop WM, Veenstra HJ, Vermeeren L, Nieweg OE, Balm AJ, Lohuis PJ. Assessment of lymphatic drainage patterns and implications for the extent of neck dissection in head and neck melanoma patients. J Surg Oncol. 2011;103(8):756–60.

    Article  PubMed  Google Scholar 

  34. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw. 2009;7(3):308–17.

    Article  PubMed  Google Scholar 

  36. Erman AB, Collar RM, Griffith KA, et al. Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancer. 2012;118(4):1040–7.

    Article  PubMed  Google Scholar 

  37. Picon AI, Coit DG, Shaha AR, et al. Sentinel lymph node biopsy for cutaneous head and neck melanoma: mapping the parotid gland. Ann Surg Oncol. 2016;23(Suppl 5):9001–9.

    Article  PubMed  Google Scholar 

  38. Schmalbach CE, Nussenbaum B, Rees RS, Schwartz J, Johnson TM, Bradford CR. Reliability of sentinel lymph node mapping with biopsy for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg. 2003;129(1):61–5.

    Article  PubMed  Google Scholar 

  39. Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–22.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Fritsch VA, Cunningham JE, Lentsch EJ. Completion lymph node dissection based on risk of nonsentinel metastasis in cutaneous melanoma of the head and neck. Otolaryngol Head Neck Surg. 2016;154(1):94–103.

    Article  PubMed  Google Scholar 

  41. Pasquali S, Spillane AJ, de Wilt JH, et al. Surgeons’ opinions on lymphadenectomy in melanoma patients with positive sentinel nodes: a worldwide web-based survey. Ann Surg Oncol. 2012;19(13):4322–9.

    Article  PubMed  Google Scholar 

  42. Reynolds HM, Smith NP, Uren RF, Thompson JF, Dunbar PR. Three-dimensional visualization of skin lymphatic drainage patterns of the head and neck. Head Neck. 2009;31(10):1316–25.

    Article  PubMed  Google Scholar 

  43. Van de Vrie W, Eggermont AM, Van Putten WL, Wiggers T. Therapeutic lymphadenectomy in melanomas of the head and neck. Head Neck. 1993;15(5):377–81.

    Article  PubMed  Google Scholar 

  44. O'Brien CJ, Petersen-Schaefer K, Ruark D, Coates AS, Menzie SJ, Harrison RI. Radical, modified, and selective neck dissection for cutaneous malignant melanoma. Head Neck. 1995;17(3):232–41.

    Article  PubMed  CAS  Google Scholar 

  45. Geltzeiler M, Monroe M, Givi B, Vetto J, Andersen P, Gross N. Regional control of head and neck melanoma with selective neck dissection. JAMA Otolaryngol Head Neck Surg. 2014;140(11):1014–8.

    Article  PubMed  Google Scholar 

  46. Supriya M, Narasimhan V, Henderson MA, Sizeland A. Managing regional metastasis in patients with cutaneous head and neck melanoma—is selective neck dissection appropriate? Am J Otolaryngol. 2014;35(5):610–6.

    Article  PubMed  Google Scholar 

  47. Shah JP, Kraus DH, Dubner S, Sarkar S. Patterns of regional lymph node metastases from cutaneous melanomas of the head and neck. Am J Surg. 1991;162(4):320–3.

    Article  PubMed  CAS  Google Scholar 

  48. Suton P, Lukšić I, Müller D, Virag M. Lymphatic drainage patterns of head and neck cutaneous melanoma: does primary melanoma site correlate with anatomic distribution of pathologically involved lymph nodes? Int J Oral Maxillofac Surg. 2012;41(4):413–20.

    Article  PubMed  CAS  Google Scholar 

  49. Thom JJ, Moore EJ, Price DL, Kasperbauer JL, Starkman SJ, Olsen KD. The role of total parotidectomy for metastatic cutaneous squamous cell carcinoma and malignant melanoma. JAMA Otolaryngol Head Neck Surg. 2014;140(6):548–54.

    Article  PubMed  Google Scholar 

  50. Wertz AP, Durham AB, Malloy KM, Johnson TM, Bradford CR, McLean SA. Total versus superficial parotidectomy for stage III melanoma. Head Neck. 2017;39(8):1665–70.

    Article  PubMed  Google Scholar 

  51. Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16(9):1049–60.

    Article  PubMed  Google Scholar 

  52. Shen P, Wanek LA, Morton DL. Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas? Ann Surg Oncol. 2000;7(8):554–9; discussion 560–1

    Article  PubMed  CAS  Google Scholar 

  53. Ballo MT, Bonnen MD, Garden AS, et al. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer. 2003;97(7):1789–96.

    Article  PubMed  Google Scholar 

  54. Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion SV. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev. 2013;6:CD008955.

    Google Scholar 

  55. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.

    Article  PubMed  CAS  Google Scholar 

  56. Coens C, Suciu S, Chiarion-Sileni V, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017;18(3):393–403.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Tarhini A. Ipilimumab or high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery. https://clinicaltrials.gov/ct2/show/NCT01274338?term=NCT01274338&rank=1. Accessed 12 Nov 2015.

  58. Testori A. Adjuvant PEG intron in ulcerated melanoma. https://www.clinicaltrials.gov/ct2/show/NCT01502696?term=NCT01502696&rank=1. Accessed 12 Nov 2015.

  59. Squibb B-M. Efficacy study of nivolumab compared to ipilimumab in prevention of recurrence of melanoma after complete resection of Stage IIIb/c or Stage IV melanoma (CheckMate 238). https://clinicaltrials.gov/ct2/show/NCT02388906?term=NCT02388906&rank=1. Accessed 13 Nov 2015.

  60. Corp. MSD. Study of pembrolizumab (MK-3475) versus placebo after complete resection of high-risk stage III melanoma (MK-3475-054/KEYNOTE-054). https://clinicaltrials.gov/ct2/show/NCT02362594?term=NCT02362594&rank=1. Accessed 13 Nov 2015.

  61. GlaxoSmithKline. A study of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib in the adjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection. (COMBI-AD). https://www.clinicaltrials.gov/ct2/show/NCT01682083?term=NCT01682083&rank=1. Accessed 14 Nov 2015.

  62. Roche H-L. BRIM8: a study of vemurafenib adjuvant therapy in patients with resected cutaneous BRAF mutant melanoma. https://clinicaltrials.gov/ct2/show/NCT01667419. Accessed 14 Nov 2015.

  63. Mordoh J. Phase II/III clinical study CSF470 plus BCG plus GM-CSF vs IFN alpha 2b in stage IIB, IIC and III melanoma patients. https://clinicaltrials.gov/ct2/show/NCT01729663?term=melanoma+AND+adjuvant&phase=23&rank=6. Accessed 14 Nov 2015.

  64. Schmidt MQ, David J, Yoshida EJ, et al. Predictors of survival in head and neck mucosal melanoma. Oral Oncol. 2017;73:36–42.

    Article  PubMed  Google Scholar 

  65. Members NP. NCCN Clinical practice guidelines in oncology: head and neck cancer. 2017. http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed 28 Aug 2017.

  66. Marcus DM, Marcus RP, Prabhu RS, et al. Rising incidence of mucosal melanoma of the head and neck in the United States. J Skin Cancer. 2012;2012:231693.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664–78.

    Article  PubMed  CAS  Google Scholar 

  68. Greaves WO, Verma S, Patel KP, et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn. 2013;15(2):220–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Wu Y, Zhong Y, Li C, Song H, Guo W, Ren G. Neck dissection for oral mucosal melanoma: caution of nodular lesion. Oral Oncol. 2014;50(4):319–24.

    Article  PubMed  Google Scholar 

  70. Yao WC, Emerick KS, Kraft S, Holbrook EH. Nasal mucosal melanosis may act as a harbinger of melanoma: a case report. Allergy Rhinol (Providence). 2016;7(3):164–7.

    Article  Google Scholar 

  71. Fuji H, Yoshikawa S, Kasami M, et al. High-dose proton beam therapy for sinonasal mucosal malignant melanoma. Radiat Oncol. 2014;9:162.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Liao JJ, Parvathaneni U, Laramore GE, et al. Fast neutron radiotherapy for primary mucosal melanomas of the head and neck. Head Neck. 2014;36(8):1162–7.

    Article  PubMed  Google Scholar 

  73. Gal TJ, Silver N, Huang B. Demographics and treatment trends in sinonasal mucosal melanoma. Laryngoscope. 2011;121(9):2026–33.

    PubMed  Google Scholar 

  74. Shuman AG, Light E, Olsen SH, et al. Mucosal melanoma of the head and neck: predictors of prognosis. Arch Otolaryngol Head Neck Surg. 2011;137(4):331–7.

    Article  PubMed  Google Scholar 

  75. Heppt MV, Roesch A, Weide B, et al. Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. Eur J Cancer. 2017;81:36–44.

    Article  PubMed  Google Scholar 

  76. Lawaetz M, Birch-Johansen F, Friis S, et al. Primary mucosal melanoma of the head and neck in Denmark, 1982–2012: Demographic and clinical aspects. A retrospective DAHANCA study. Acta Oncol. 2016;55(8):1001–8.

    Article  PubMed  Google Scholar 

  77. Swegal W, Koyfman S, Scharpf J, et al. Endoscopic and open surgical approaches to locally advanced sinonasal melanoma: comparing the therapeutic benefits. JAMA Otolaryngol Head Neck Surg. 2014;140(9):840–5.

    Article  PubMed  Google Scholar 

  78. Cao W, Guan B, Yu A, et al. Treatment and outcomes of endoscopic surgery and traditional open resection in sinonasal mucosal melanoma. Acta Otolaryngol. 2017;137(8):862–7.

    Article  PubMed  Google Scholar 

  79. Plavc G, But-Hadžić J, Aničin A, Lanišnik B, Didanović V, Strojan P. Mucosal melanoma of the head and neck: a population-based study from Slovenia, 1985–2013. Radiat Oncol. 2016;11(1):137.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Konuthula N, Khan MN, Parasher A, et al. The presentation and outcomes of mucosal melanoma in 695 patients. Int Forum Allergy Rhinol. 2017;7(1):99–105.

    Article  PubMed  Google Scholar 

  81. Yang X, Ren GX, Zhang CP, et al. Neck dissection and post-operative chemotherapy with dimethyl triazeno imidazole carboxamide and cisplatin protocol are useful for oral mucosal melanoma. BMC Cancer. 2010;10:623.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Sun CZ, Chen YF, Jiang YE, Hu ZD, Yang AK, Song M. Treatment and prognosis of oral mucosal melanoma. Oral Oncol. 2012;48(7):647–52.

    Article  PubMed  Google Scholar 

  83. Wushou A, Hou J, Zhao YJ, Miao XC. Postoperative adjuvant radiotherapy improves loco-regional recurrence of head and neck mucosal melanoma. J Craniomaxillofac Surg. 2015;43(4):553–8.

    Article  PubMed  Google Scholar 

  84. Krengli M, Jereczek-Fossa BA, Kaanders JH, Masini L, Beldì D, Orecchia R. What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck? Crit Rev Oncol Hematol. 2008;65(2):121–8.

    Article  PubMed  Google Scholar 

  85. Moreno MA, Roberts DB, Kupferman ME, et al. Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center. Cancer. 2010;116(9):2215–23.

    PubMed  Google Scholar 

  86. Jarrom D, Paleri V, Kerawala C, et al. Mucosal melanoma of the upper airways tract mucosal melanoma: a systematic review with meta-analyses of treatment. Head Neck. 2017;39(4):819–25.

    Article  PubMed  Google Scholar 

  87. Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 2005;103(2):313–9.

    Article  PubMed  Google Scholar 

  88. Lian B, Si L, Cui C, et al. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res. 2013;19(16):4488–98.

    Article  PubMed  CAS  Google Scholar 

  89. Schaefer T, Satzger I, Gutzmer R. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: a retrospective analysis of 75 patients. Medicine (Baltimore). 2017;96(1):e5753.

    Article  Google Scholar 

  90. Kim KB, Alrwas A. Treatment of KIT-mutated metastatic mucosal melanoma. Chin Clin Oncol. 2014;3(3):35.

    PubMed  Google Scholar 

  91. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327–34.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Postow MA, Luke JJ, Bluth MJ, et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013;18(6):726–32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Ascierto PA, Vanella V, Grimaldi AM, et al. Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. Cancer Immunol Immunother. 2016;65(11):1395–400.

    Article  PubMed  CAS  Google Scholar 

  94. Members NP. NCCN Clinical practice guidelines in oncology: basal cell skin cancer. 2017. https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf. Accessed 2 Sept 2017.

  95. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007;1:CD003412.

    Google Scholar 

  96. van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014;50(17):3011–20.

    Article  PubMed  Google Scholar 

  97. Avril MF, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer. 1997;76(1):100–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  98. Petit JY, Avril MF, Margulis A, et al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg. 2000;105(7):2544–51.

    Article  PubMed  CAS  Google Scholar 

  99. Jackson JE, Dickie GJ, Wiltshire KL, et al. Radiotherapy for perineural invasion in cutaneous head and neck carcinomas: toward a risk-adapted treatment approach. Head Neck. 2009;31(5):604–10.

    Article  PubMed  Google Scholar 

  100. Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32(3):372–81.

    Article  PubMed  CAS  Google Scholar 

  102. Pharmaceuticals R. NCT03132636: PD-1 in patients with advanced basal cell carcinoma who experienced progression of disease on hedgehog pathway inhibitor therapy, or were intolerant of prior hedgehog pathway inhibitor therapy. https://clinicaltrials.gov/ct2/show/NCT03132636. Accessed 3 Sept 2017.

  103. Durham AB, Lowe L, Malloy KM, et al. Sentinel lymph node biopsy for cutaneous squamous cell carcinoma on the head and neck. JAMA Otolaryngol Head Neck Surg. 2016;142(12):1171–6.

    Article  PubMed  Google Scholar 

  104. Martinez JC, Cook JL. High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: is there a therapeutic role for elective neck dissection? Dermatol Surg. 2007;33(4):410–20.

    PubMed  CAS  Google Scholar 

  105. Audet N, Palme CE, Gullane PJ, et al. Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome. Head Neck. 2004;26(8):727–32.

    Article  PubMed  Google Scholar 

  106. Moore BA, Weber RS, Prieto V, et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005;115(9):1561–7.

    Article  PubMed  Google Scholar 

  107. Members NP. NCCN Clinical practice guidelines in oncology: squamous cell skin cancer 2017. https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. Accessed 2 Sept 2017.

  108. Pharmaceuticals R. NCT02760498: study of REGN2810 in patients with advanced cutaneous squamous cell carcinoma. https://clinicaltrials.gov/ct2/show/NCT02760498. Accessed 2 Sept 2017.

  109. Kudchadkar R. NCT02964559: Pembrolizumab in patients with locally advanced or metastatic skin cancer. https://clinicaltrials.gov/ct2/show/NCT02964559. Accessed 3 Sept 2017.

  110. Samimi M, Gardair C, Nicol JT, Arnold F, Touzé A, Coursaget P. Merkel cell polyomavirus in merkel cell carcinoma: clinical and therapeutic perspectives. Semin Oncol. 2015;42(2):347–58.

    Article  PubMed  Google Scholar 

  111. Members NP. NCCN clinical practice guidelines in oncology: merkel cell carcinoma. 2017; https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf. Accessed 3 Sept 2017.

  112. Kachare SD, Wong JH, Vohra NA, Zervos EE, Fitzgerald TL. Sentinel lymph node biopsy is associated with improved survival in Merkel cell carcinoma. Ann Surg Oncol. 2014;21(5):1624–30.

    Article  PubMed  Google Scholar 

  113. Thompson JF, Hruby G. The role of sentinel lymph node biopsy in patients with merkel cell carcinoma: uncertainty prevails. Ann Surg Oncol. 2014;21(5):1517–9.

    Article  PubMed  Google Scholar 

  114. Fritsch VA, Camp ER, Lentsch EJ. Sentinel lymph node status in Merkel cell carcinoma of the head and neck: not a predictor of survival. Head Neck. 2014;36(4):571–9.

    Article  PubMed  Google Scholar 

  115. Sadeghi R, Adinehpoor Z, Maleki M, Fallahi B, Giovanella L, Treglia G. Prognostic significance of sentinel lymph node mapping in Merkel cell carcinoma: systematic review and meta-analysis of prognostic studies. Biomed Res Int. 2014;2014:489536.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Bhatia S, Storer BE, Iyer JG, et al. Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: survival analyses of 6908 cases from the National Cancer Data Base. J Natl Cancer Inst. 2016;108(9)

    Article  PubMed  PubMed Central  Google Scholar 

  117. Lewis KG, Weinstock MA, Weaver AL, Otley CC. Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol. 2006;142(6):693–700.

    Article  PubMed  Google Scholar 

  118. Jouary T, Leyral C, Dreno B, et al. Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. Ann Oncol. 2012;23(4):1074–80.

    Article  PubMed  CAS  Google Scholar 

  119. Chen MM, Roman SA, Sosa JA, Judson BL. The role of adjuvant therapy in the management of head and neck merkel cell carcinoma: an analysis of 4815 patients. JAMA Otolaryngol Head Neck Surg. 2015;141(2):137–41.

    Article  PubMed  Google Scholar 

  120. Chapuis A. NCT02584829: localized radiation therapy or recombinant interferon beta and avelumab with or without cellular adoptive immunotherapy in treating patients with metastatic merkel cell carcinoma. https://clinicaltrials.gov/ct2/show/NCT02584829. Accessed 3 Sept 2017.

  121. Rabinowits G. NCT02514824: MLN0128 in recurrent/metastatic merkel cell carcinoma. https://clinicaltrials.gov/ct2/show/NCT02514824. Accessed 3 Sept 2017.

  122. Niethammer A. NCT02465957: QUILT-3.009: study of aNK infusions in combination with ALT-803 in patients with stage III (IIIB) or stage (IV) merkel cell carcinoma. https://clinicaltrials.gov/ct2/show/NCT02465957. Accessed 3 Sept 2017.

  123. Kim S. NCT03071406: randomized study of nivolumab+Ipilimumab+/− SBRT for metastatic merkel cell carcinoma. https://clinicaltrials.gov/ct2/show/NCT03071406. Accessed 3 Sept 2017.

Download references

Acknowledgement

No financial disclosures or conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Otolaryngology—Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA

    Joseph Zenga M.D. & Kevin Emerick M.D.

  2. Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology—Head and Neck Surgery, Johns Hopkins University School of Medicine, Bethesda, MD, USA

    Shaun Desai M.D.

Authors
  1. Joseph Zenga M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin Emerick M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shaun Desai M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaun Desai M.D. .

Editor information

Editors and Affiliations

  1. Louisiana State University, New Orleans, Louisiana, USA

    Adam I. Riker

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zenga, J., Emerick, K., Desai, S. (2018). Surgical Management of Head and Neck Melanoma. In: Riker, A. (eds) Melanoma. Springer, Cham. https://doi.org/10.1007/978-3-319-78310-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-78310-9_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-78309-3

  • Online ISBN: 978-3-319-78310-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation